Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Cisplatin as Radiosensitizers in Bladder Cancer Radiotherapy
IRCT20180815040801N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of capecitabine and cisplatin in bladder cancer, sponsored by Tehran University of Medical Sciences. Started Jan 2018; status: completed.
02
Drugs
capecitabinecisplatin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on IRCT20180815040801N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180815040801N1.